0001209191-23-004337.txt : 20230120 0001209191-23-004337.hdr.sgml : 20230120 20230120193225 ACCESSION NUMBER: 0001209191-23-004337 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230120 DATE AS OF CHANGE: 20230120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henderson Molly CENTRAL INDEX KEY: 0001363812 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39094 FILM NUMBER: 23542285 MAIL ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001783183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824151574 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (877) 742-8466 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-19 0 0001783183 Phathom Pharmaceuticals, Inc. PHAT 0001363812 Henderson Molly C/O PHATHOM PHARMACEUTICALS, INC. 100 CAMPUS DRIVE, SUITE 102 FLORHAM NJ 07932 0 1 0 0 CFO and CBO Common Stock 2023-01-19 4 A 0 33000 0.00 A 78047 D Common Stock 338.86 I by 401(k) Stock Option (Right to Buy) 8.35 2023-01-19 4 A 0 55000 0.00 A 2033-01-18 Common Stock 55000 55000 D Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Includes 1,706 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023. The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. /s/ Larry Miller, Attorney-in-Fact for Molly Henderson 2023-01-20